Discover

DXCM
DexCom, Inc.
68.86
2 x 63.01
2 x 74.35
bid
ask
+
1.51
2.24%
2 @ 05:23 AM
69.15 +0.29 (0.42%)
Ytd3.75%
1y-17.61%
67.87
day range
69.66
54.11
52 week range
89.98
Open68.16Prev Close67.35Low67.87High69.66Mkt Cap26.57B
Vol4.75MAvg Vol5.65MEPS2.33P/E29.55Forward P/E22.34
Beta1.44Short Ratio2.40Inst. Own102.40%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2950-d Avg67.51200-d Avg67.161yr Est85.24

DXCM News

DexCom: The Growth Thesis Still Needs To Be Proven
seekingalpha.com
DexCom: The Growth Thesis Still Needs To Be Proven

DexCom faces a pivotal transition as GLP-1 adoption threatens its core insulin-treated diabetes mark

Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
zacks.com
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?

DXCM outpaces Abbott with expanding CGM access, new product launches and broader coverage, making it

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
benzinga.com
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page fo

benzinga.com
Deutsche Bank Initiates Coverage On DexCom with Buy Rating, Announces Price Target of $86

Deutsche Bank analyst Kieran Ryan initiates coverage on DexCom (NASDAQ:DXCM) with a Buy rating an

benzinga.com
Here's How Much You Would Have Made Owning DexCom Stock In The Last 20 Years

Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor
benzinga.com
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor

FDA Clears Dexcom's OTC Stelo CGM For Children Ages 2 And Older, Expanding Access To Real-Time G

benzinga.com
Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $88

Piper Sandler analyst Matt O'Brien maintains DexCom (NASDAQ:DXCM) with a Overweight and raise

benzinga.com
FDA Clears First Over-The-Counter Continuous Glucose Monitor For Children

https://www.fda.gov/news-events/press-announcements/fda-clears-first-over-counter-continuous-glucose

benzinga.com
TD Cowen Maintains Buy on DexCom, Raises Price Target to $95

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

benzinga.com
Mizuho Maintains Outperform on DexCom, Raises Price Target to $85

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes
benzinga.com
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

DexCom CONNECT trial found G7 reduced A1C and improved glucose control in Type 2 diabetes patients n

benzinga.com
Reported Saturday, Dexcom CONNECT Trial Shows G7 Delivers 1.6% Average A1C Reduction In Type 2 Diabe

Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care

benzinga.com
Stifel Maintains Buy on DexCom, Raises Price Target to $90

Stifel analyst Jonathan Block maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price targ

benzinga.com
DexCom To Present New Data And Announce Strategic Business Initiatives At American Diabetes Associat

CONNECT study will demonstrate Dexcom CGM benefits for adults with Type 2 diabetes not using insulin

benzinga.com
Citigroup Maintains Buy on DexCom, Raises Price Target to $84

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

benzinga.com
DexCom Reveals Stolen Lots Of Scrapped Dexcom G7 Sensors Were Sold And Used By Customers, Launches I

Through ongoing quality and accounting reviews, Dexcom discovered two lots of scrapped product were

benzinga.com
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years

benzinga.com
Canaccord Genuity Maintains Buy on DexCom, Lowers Price Target to $82

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and lowers t

benzinga.com
B of A Securities Maintains Buy on DexCom, Lowers Price Target to $80

B of A Securities analyst Travis Steed maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the p

benzinga.com
Barclays Maintains Underweight on DexCom, Lowers Price Target to $64

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the pri

benzinga.com
DexCom Rolls Out Glucose Monitoring System Dexcom Flex In Germany

DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today announced Dexco

Diabetes Tech Player DexCom Lays Out 2030 Growth Vision
benzinga.com
Diabetes Tech Player DexCom Lays Out 2030 Growth Vision

DexCom Sets 2030 Margin Targets, Projects Double-Digit Revenue Growth, Authorizes $1 Billion Share B

benzinga.com
Reported May 14, 2026: DexCom To Add Two Independent Directors And Expand Operations And Innovation

Will Add Two Independent Directors with MedTech and Operations Experience to be Named at a Later Dat

benzinga.com
Citigroup Maintains Buy on DexCom, Lowers Price Target to $79

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price t

benzinga.com
Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $100

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:DXCM) with a Buy and raises t

benzinga.com
TD Cowen Maintains Buy on DexCom, Lowers Price Target to $75

TD Cowen analyst Joshua Jennings maintains DexCom (NASDAQ:DXCM) with a Buy and lowers the price t

benzinga.com
Barclays Maintains Underweight on DexCom, Lowers Price Target to $67

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and lowers the pri

DexCom Q1 2026 Earnings Call Transcript
benzinga.com
DexCom Q1 2026 Earnings Call Transcript

benzinga.com
DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B vs $5.230B Est

2026 Annual GuidanceDexcom is raising fiscal year 2026 guidance for Non-GAAP Operating Margin and Ad

benzinga.com
DexCom Q1 Adj. EPS $0.56 Beats $0.47 Estimate, Sales $1.191B Beat $1.175B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.56 per share which beat the analyst consensus

Earnings Scheduled For April 30, 2026
benzinga.com
Earnings Scheduled For April 30, 2026

Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves
benzinga.com
Diabetes Focused MiniMed Recovery Story Builds As Pipeline Improves

MiniMed shows improved pipeline and valuation upside as insulin pump adoption grows despite rising c

GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech
benzinga.com
GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech

GlucoTrack targets a Q2 2026 FDA IDE filing for CGM, backed by clinical data, manufacturing strategy

benzinga.com
Citigroup Maintains Buy on DexCom, Raises Price Target to $84

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:DXCM) with a Buy and raises the price t

benzinga.com
Dexcom Presents New G7 Registry Data Showing A1C And Weight Management Improvements In Non-Insulin T

New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers

Demystifying DexCom: Insights From 12 Analyst Reviews
benzinga.com
Demystifying DexCom: Insights From 12 Analyst Reviews

benzinga.com
Here's How Much You Would Have Made Owning DexCom Stock In The Last 10 Years

P/E Ratio Insights for DexCom
benzinga.com
P/E Ratio Insights for DexCom

benzinga.com
Truist Securities Reiterates Buy on DexCom, Lowers Price Target to $80

Truist Securities analyst Richard Newitter reiterates DexCom (NASDAQ:DXCM) with a Buy and lowers

Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?
benzinga.com
Small Caps, Silver Rally As Inflation Cools Further: What's Moving Markets Friday?

After Thursday's broad-based tech selloff, Wall Street staged a rebound as a softer-than-expecte

benzinga.com
Barclays Maintains Underweight on DexCom, Raises Price Target to $72

Barclays analyst Matt Miksic maintains DexCom (NASDAQ:DXCM) with a Underweight and raises the pri

Coinbase, Rivian Automotive, Instacart, HubSpot And Other Big Stocks Moving Higher On Friday
benzinga.com
Coinbase, Rivian Automotive, Instacart, HubSpot And Other Big Stocks Moving Higher On Friday

benzinga.com
Wells Fargo Maintains Overweight on DexCom, Lowers Price Target to $85

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:DXCM) with a Overweight and lowers t

benzinga.com
Mizuho Maintains Outperform on DexCom, Raises Price Target to $90

Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the pr

7 Analysts Have This To Say About DexCom
benzinga.com
7 Analysts Have This To Say About DexCom

DexCom Reports Better-Than-Expected Q4 Results: Details
benzinga.com
DexCom Reports Better-Than-Expected Q4 Results: Details

Here's a look at the Q4 earnings report from DexCom.

Insights into DexCom Q4 Earnings
benzinga.com
Insights into DexCom Q4 Earnings

benzinga.com
DexCom Affirms FY2026 Sales Guidance of $5.160B-$5.250B

DexCom (NASDAQ:DXCM) affirms FY2026 sales outlook from $5.160 billion-$5.250 billion to $5.160 billi

benzinga.com
DexCom Q4 Adj. EPS $0.68 Beats $0.65 Estimate, Sales $1.260B Beat $1.246B Estimate

DexCom (NASDAQ:DXCM) reported quarterly earnings of $0.68 per share which beat the analyst consensus

Earnings Scheduled For February 12, 2026
benzinga.com
Earnings Scheduled For February 12, 2026